Neutralizing antibodies to African swine fever virus proteins p30, p54, and p72 are not sufficient for antibody-mediated protection.
Although antibody-mediated immune mechanisms have been shown to be important in immunity to ASF, it remains unclear what role virus neutralizing antibodies play in the protective response. Virus neutralizing epitopes have been identified on three viral proteins, p30, p54, and p72. To evaluate the role(s) of these proteins in protective immunity, pigs were immunized with baculovirus-expressed p30, p54, p72, and p22 from the pathogenic African swine fever virus (ASFV) isolate Pr4. ASFV specific neutralizing antibodies were detected in test group animals. Following immunization, animals were challenged with 10(4) TCID(50) of Pr4 virus. In comparison to the control group, test group animals exhibited a 2-day delay to onset of clinical disease and reduced viremia levels at 2 days postinfection (DPI); however, by 4 DPI, there was no significant difference between the two groups and all animals in both groups died between 7 and 10 DPI. These results indicate that neutralizing antibodies to these ASFV proteins are not sufficient for antibody-mediated protection.
Plum Island Animal Disease Center, Agricultural Research Service, USDA, Greenport, NY 11944, USA. jneilan@piadc.ars.usda.gov
J G
JG
Neilan
L
L
Zsak
Z
Z
Lu
T G
TG
Burrage
G F
GF
Kutish
D L
DL
Rock
D000357:African Swine Fever / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D000358:African Swine Fever Virus / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000378:metabolism; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D004195:Disease Models, Animal; D005822:Genetic Vectors; D007110:Immunity, Active; D009500:Neutralization Tests; D010750:Phosphoproteins / Q000235:genetics / Q000276:immunology*; D013552:Swine; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology*
D000914:Antibodies, Viral; D036022:Capsid Proteins; D010750:Phosphoproteins; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D015678:Viral Structural Proteins; D014765:Viral Vaccines; C063745:capsid protein p72, African swine fever virus; C093921:p54 protein, African swine fever virus; C074960:P30 protein, African Swine Fever Virus